Day One Biopharmaceuticals (DAWN) Short Interest Ratio & Short Volume $7.90 +0.46 (+6.18%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Day One Biopharmaceuticals Short Interest DataDay One Biopharmaceuticals (DAWN) has a short interest of 17.48 million shares, representing 23.53% of the float (the number of shares available for trading by the public). This marks a 2.70% increase in short interest from the previous month. The short interest ratio (days to cover) is 14.6, indicating that it would take 14.6 days of the average trading volume of 1.09 million shares to cover all short positions.Current Short Interest17,480,000 sharesPrevious Short Interest17,020,000 sharesChange Vs. Previous Month+2.70%Dollar Volume Sold Short$138.62 millionShort Interest Ratio14.6 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares101,354,000 sharesFloat Size74,280,000 sharesShort Percent of Float23.53%Today's Trading Volume1,143,281 sharesAverage Trading Volume1,085,517 sharesToday's Volume Vs. Average105% Short Selling Day One Biopharmaceuticals? Sign up to receive the latest short interest report for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDAWN Short Interest Over TimeDAWN Days to Cover Over TimeDAWN Percentage of Float Shorted Over Time Day One Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202517,480,000 shares $138.62 million +2.7%23.5%14.6 $7.93 3/15/202517,020,000 shares $138.20 million -6.4%22.9%14.5 $8.12 2/28/202518,180,000 shares $164.71 million +3.9%24.5%15.5 $9.06 2/15/202517,500,000 shares $214.55 million +1.2%23.7%17.5 $12.26 1/31/202517,290,000 shares $213.88 million +4.2%23.8%16.5 $12.37 1/15/202516,600,000 shares $197.04 million -10.5%22.9%14.7 $11.87 12/31/202418,550,000 shares $235.03 million +2.5%25.5%17.5 $12.67 12/15/202418,100,000 shares $230.78 million -7.1%24.9%16.6 $12.75 11/30/202419,490,000 shares $271.50 million +4.5%28.5%17.9 $13.93 11/15/202418,660,000 shares $248.36 million +3.6%27.3%17.6 $13.31 Get the Latest News and Ratings for DAWN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/31/202418,020,000 shares $265.25 million +12.8%26.4%17.7 $14.72 10/15/202415,980,000 shares $236.98 million +2.0%26.9%16 $14.83 9/30/202415,670,000 shares $218.28 million +3.8%26.4%16 $13.93 9/15/202415,100,000 shares $213.36 million +7.2%25.5%15.4 $14.13 8/31/202414,080,000 shares $194.87 million +3.8%23.8%14.4 $13.84 8/15/202413,570,000 shares $193.10 million +11.1%22.9%13.6 $14.23 7/31/202412,210,000 shares $174.73 million +6.0%20.1%12.5 $14.31 7/15/202411,520,000 shares $180.86 million +10.3%19.0%9.8 $15.70 6/30/202410,440,000 shares $143.86 million +1.5%17.2%8.9 $13.78 6/15/202410,290,000 shares $129.76 million -3.5%17.0%9 $12.61 5/31/202410,660,000 shares $141.46 million +0.6%17.6%9.5 $13.27 5/15/202410,600,000 shares $174.05 million -5.3%17.5%9.7 $16.42 4/30/202411,190,000 shares $191.35 million +25.2%18.5%10.7 $17.10 4/15/20248,940,000 shares $123.82 million -0.5%15.2%10.6 $13.85 3/31/20248,980,000 shares $148.35 million -6.6%15.2%14.5 $16.52 3/15/20249,610,000 shares $138.29 million -0.9%16.3%16.6 $14.39 2/29/20249,700,000 shares $162.28 million -0.2%16.5%17.3 $16.73 2/15/20249,720,000 shares $149.30 million +6.2%16.6%19.5 $15.36 1/31/20249,150,000 shares $137.71 million -15.3%15.5%17.4 $15.05 1/15/202410,800,000 shares $150.55 million +0.5%19.1%16.7 $13.94 12/31/202310,750,000 shares $156.95 million -2.3%19.0%15.1 $14.60 12/15/202311,000,000 shares $156.86 million +2.3%19.4%14.8 $14.26 11/30/202310,750,000 shares $124.49 million -0.7%19.0%13 $11.58 11/15/202310,830,000 shares $130.72 million -8.5%19.2%13.1 $12.07 10/31/202311,840,000 shares $140.07 million +4.3%21.0%14.1 $11.83 10/15/202311,350,000 shares $125.64 million -7.8%20.1%14.7 $11.07 9/30/202312,310,000 shares $151.04 million -0.5%21.3%16.7 $12.27 9/15/202312,370,000 shares $172.19 million +2.7%21.4%16 $13.92 8/31/202312,050,000 shares $162.55 million -0.2%20.4%13.2 $13.49 8/15/202312,070,000 shares $166.32 million -12.4%20.4%10.3 $13.78Elon Reveals Why There Soon Won’t Be Any Money For Social Security (Ad)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.See why thousands of forward-thinking retirement savers are now requesting this FREE 2025 Wealth Pro 7/31/202313,780,000 shares $182.45 million +1.0%30.1%11.5 $13.24 7/15/202313,640,000 shares $158.91 million -2.4%29.8%10.7 $11.65 6/30/202313,980,000 shares $166.92 million +3.5%30.6%11 $11.94 6/15/202313,510,000 shares $177.52 million +35.1%29.6%10.1 $13.14 5/31/202310,000,000 shares $133 million +7.2%21.5%8.8 $13.30 5/15/20239,330,000 shares $129.50 million +2.3%20.1%11.3 $13.88 4/30/20239,120,000 shares $113.09 million +16.0%20.0%11.7 $12.40 4/15/20237,860,000 shares $96.99 million +6.1%17.3%11.6 $12.34 3/31/20237,410,000 shares $99.07 million +11.3%16.3%10.7 $13.37 3/15/20236,660,000 shares $124.34 million +12.1%14.6%12.1 $18.67 2/28/20235,940,000 shares $109.41 million +4.4%13.0%10.7 $18.42 2/15/20235,690,000 shares $111.18 million +6.6%12.5%10.7 $19.54 1/31/20235,340,000 shares $116.25 million -4.5%11.6%10.1 $21.77 1/15/20235,590,000 shares $127.62 million +25.1%14.0%10.5 $22.83 12/30/20224,470,000 shares $96.19 million +3.5%11.2%8.4 $21.52 12/15/20224,320,000 shares $92.53 million -1.1%11.0%8.6 $21.42 11/30/20224,370,000 shares $92.78 million -4.2%11.1%7.3 $21.23 11/15/20224,560,000 shares $99.82 million -9.5%11.6%7.5 $21.89 10/31/20225,040,000 shares $106.55 million -7.9%12.7%7.7 $21.14 10/15/20225,470,000 shares $114.21 million -8.5%14.6%8.5 $20.88 9/30/20225,980,000 shares $119.78 million -3.1%17.0%9.5 $20.03 9/15/20226,170,000 shares $140.55 million -9.3%17.5%9 $22.78 8/31/20226,800,000 shares $159.73 million -6.7%21.3%4 $23.49 8/15/20227,290,000 shares $182.25 million -0.7%22.9%4.2 $25.00 7/31/20227,340,000 shares $125.73 million -6.0%24.3%4.4 $17.13 7/15/20227,810,000 shares $149.48 million +8.2%25.8%4.8 $19.14 6/30/20227,220,000 shares $129.24 million +0.6%23.2%4.5 $17.90 6/15/20227,180,000 shares $109.50 million +37.3%28.1%4.8 $15.25 5/31/20225,230,000 shares $32.53 million +9.2%23.8%17.8 $6.22 5/15/20224,790,000 shares $36.64 million +11.1%21.8%21.1 $7.65 4/30/20224,310,000 shares $36.72 million +6.4%19.8%20.2 $8.52 4/15/20224,050,000 shares $45.85 million +2.3%18.6%18.6 $11.32 3/31/20223,960,000 shares $39.28 million +0.5%N/A16.7 $9.92 3/15/20223,940,000 shares $41.29 million -1.3%18.1%16.1 $10.48 2/28/20223,990,000 shares $54.50 million +0.8%18.4%15.1 $13.66 2/15/20223,960,000 shares $54.61 million +4.8%18.2%14.6 $13.79 1/31/20223,780,000 shares $55.76 million +11.2%17.2%15.3 $14.75 1/15/20223,400,000 shares $47.91 million -1.2%N/A15.3 $14.09 12/31/20213,440,000 shares $57.96 million +30.3%14.8%18.7 $16.85 12/15/20212,640,000 shares $48.18 million +38.2%11.4%16 $18.25 11/30/20211,910,000 shares $35.09 million +6.1%8.8%16.2 $18.37 11/15/20211,800,000 shares $38.27 million -3.7%8.6%19.1 $21.26 10/29/20211,870,000 shares $45.70 million +1.6%8.9%17.7 $24.44 10/15/20211,840,000 shares $40.76 million +3.4%8.8%17.1 $22.15 9/30/20211,780,000 shares $42.24 million +6.6%8.5%16.2 $23.73 9/15/20211,670,000 shares $41.63 million +7.7%8.0%14.9 $24.93 8/31/20211,550,000 shares $43.14 million +22.1%7.8%19 $27.83 8/13/20211,270,000 shares $31.17 million No Change6.4%8.8 $24.54 DAWN Short Interest - Frequently Asked Questions What is Day One Biopharmaceuticals' current short interest? Short interest is the volume of Day One Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 17,480,000 shares of DAWN short. 23.53% of Day One Biopharmaceuticals' shares are currently sold short. Learn More on Day One Biopharmaceuticals' current short interest. What is a good short interest ratio for Day One Biopharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 15.0. Learn More on Day One Biopharmaceuticals's short interest ratio. Which institutional investors are shorting Day One Biopharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Day One Biopharmaceuticals: J. Goldman & Co LP, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Concourse Financial Group Securities Inc., and Barclays PLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Day One Biopharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.53% of Day One Biopharmaceuticals' floating shares are currently sold short. Is Day One Biopharmaceuticals' short interest increasing or decreasing? Day One Biopharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 17,480,000 shares, an increase of 2.7% from the previous total of 17,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Day One Biopharmaceuticals' float size? Day One Biopharmaceuticals currently has issued a total of 101,354,000 shares. Some of Day One Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Day One Biopharmaceuticals currently has a public float of 74,280,000 shares. How does Day One Biopharmaceuticals' short interest compare to its competitors? 23.53% of Day One Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Day One Biopharmaceuticals: Scholar Rock Holding Co. (21.52%), Protagonist Therapeutics, Inc. (8.35%), Crinetics Pharmaceuticals, Inc. (9.80%), SpringWorks Therapeutics, Inc. (12.05%), Organon & Co. (5.89%), Catalyst Pharmaceuticals, Inc. (7.47%), Viking Therapeutics, Inc. (24.12%), Xenon Pharmaceuticals Inc. (5.48%), MoonLake Immunotherapeutics (12.03%), Alvotech (0.59%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Day One Biopharmaceuticals stock? Short selling DAWN is an investing strategy that aims to generate trading profit from Day One Biopharmaceuticals as its price is falling. DAWN shares are trading up $0.46 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Day One Biopharmaceuticals? A short squeeze for Day One Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DAWN, which in turn drives the price of the stock up even further. How often is Day One Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DAWN, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies SRRK Short Interest PTGX Short Interest CRNX Short Interest SWTX Short Interest OGN Short Interest CPRX Short Interest VKTX Short Interest XENE Short Interest MLTX Short Interest ALVO Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DAWN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.